JP2023530092A5 - - Google Patents
Info
- Publication number
- JP2023530092A5 JP2023530092A5 JP2022576058A JP2022576058A JP2023530092A5 JP 2023530092 A5 JP2023530092 A5 JP 2023530092A5 JP 2022576058 A JP2022576058 A JP 2022576058A JP 2022576058 A JP2022576058 A JP 2022576058A JP 2023530092 A5 JP2023530092 A5 JP 2023530092A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- section
- enantiomer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036382P | 2020-06-08 | 2020-06-08 | |
| US63/036,382 | 2020-06-08 | ||
| US202063046496P | 2020-06-30 | 2020-06-30 | |
| US63/046,496 | 2020-06-30 | ||
| US202063048616P | 2020-07-06 | 2020-07-06 | |
| US63/048,616 | 2020-07-06 | ||
| US202063055897P | 2020-07-23 | 2020-07-23 | |
| US63/055,897 | 2020-07-23 | ||
| US202063062434P | 2020-08-06 | 2020-08-06 | |
| US63/062,434 | 2020-08-06 | ||
| US202163149223P | 2021-02-13 | 2021-02-13 | |
| US63/149,223 | 2021-02-13 | ||
| US202163165731P | 2021-03-24 | 2021-03-24 | |
| US63/165,731 | 2021-03-24 | ||
| PCT/US2021/036479 WO2021252538A2 (en) | 2020-06-08 | 2021-06-08 | Advantageous benzofuran compositions for mental disorders or enhancement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530092A JP2023530092A (ja) | 2023-07-13 |
| JP2023530092A5 true JP2023530092A5 (https=) | 2024-06-12 |
Family
ID=78845853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576058A Pending JP2023530092A (ja) | 2020-06-08 | 2021-06-08 | 精神障害又は精神高揚に有利なベンゾフラン組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11767305B2 (https=) |
| EP (1) | EP4161503A4 (https=) |
| JP (1) | JP2023530092A (https=) |
| KR (1) | KR20230066313A (https=) |
| CN (2) | CN116075300B (https=) |
| AU (1) | AU2021289434A1 (https=) |
| CA (1) | CA3179785A1 (https=) |
| IL (1) | IL298769A (https=) |
| MX (1) | MX2022015613A (https=) |
| WO (1) | WO2021252538A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| WO2020157972A1 (en) * | 2019-02-01 | 2020-08-06 | Nec Corporation | Estimation apparatus, method and program |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| CN116075300B (zh) * | 2020-06-08 | 2025-08-05 | 泰科根公司 | 用于精神障碍或精神增强的有利苯并呋喃组合物 |
| CN116209657A (zh) | 2020-08-06 | 2023-06-02 | 泰科根公司 | 用于精神障碍或增强的2-氨基茚满化合物 |
| CN116634912A (zh) * | 2020-12-23 | 2023-08-22 | 新埃莫斯欧洲有限责任公司 | 电动抽吸头 |
| WO2022251699A1 (en) * | 2021-05-28 | 2022-12-01 | Adamo Bioscience Inc. | Compositions and methods for treatment of sexual dysfunction and related diseases, disorders, and conditions |
| AU2022283967A1 (en) | 2021-06-03 | 2024-01-18 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| EP4370114A4 (en) * | 2021-07-14 | 2025-12-24 | Mydecine Innovations Group Inc | NEW SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| EP4396305B1 (en) | 2021-09-01 | 2026-05-06 | EmpathBio, Inc. | Synthesis of mdma or its optically active (r)- or (s)-mdma isomers |
| WO2023056102A1 (en) | 2021-10-01 | 2023-04-06 | ATAI Life Sciences AG | Novel prodrugs of mdma, mda, and derivatives thereof |
| WO2023107653A2 (en) * | 2021-12-08 | 2023-06-15 | Tactogen Inc | Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
| IL313455A (en) | 2021-12-15 | 2024-08-01 | Delix Therapeutics Inc | Phenoxy and benzyloxy modified psychroplastogens and their uses |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024206712A1 (en) * | 2023-03-31 | 2024-10-03 | Tactogen Inc. | Advantageous fluorobenzofurans for the treatment of mental disorders or enhancement |
| EP4727538A2 (en) * | 2023-06-15 | 2026-04-22 | Tactogen Inc. | New formulations for mental disorders or mental enhancement |
| WO2025137342A2 (en) * | 2023-12-19 | 2025-06-26 | 2A Biosciences, Inc. | 5-carboxamido and 5-carboxyalkyl phenethylamines |
| TW202602861A (zh) * | 2024-03-08 | 2026-01-16 | 新加坡商歐托梅拉公司 | 用於靶向自噬之苯并呋喃衍生物 |
| WO2025217471A1 (en) * | 2024-04-10 | 2025-10-16 | 2A Biosciences, Inc. | 2-hemifly phenethylamines |
| CN120865133A (zh) * | 2024-04-30 | 2025-10-31 | 山东全重生物医药科技有限公司 | 一类单胺递质再摄取抑制剂化合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9406823A (pt) | 1993-06-14 | 1996-03-26 | Pfizer | Aminas secundárias e agentes anti-diabéticos e antiobesidade |
| JP2000511518A (ja) | 1996-05-14 | 2000-09-05 | グラクソ、グループ、リミテッド | 時間生物学的薬剤としてのベンゾフランおよびベンゾピラン |
| US7045545B1 (en) | 1999-01-27 | 2006-05-16 | Eli Lilly And Company | Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists |
| JP2002535396A (ja) | 1999-01-27 | 2002-10-22 | イーライ・リリー・アンド・カンパニー | セロトニン（５−ｈｔ（２ｃ））アゴニストとしてのアミノアルキルベンゾフラン類 |
| US20050032873A1 (en) * | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| US7218867B2 (en) | 2004-08-27 | 2007-05-15 | Static Control Components, Inc. | Systems and methods for imaging components |
| CA2604915A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combinations for the treatment or prevention of depression |
| US7368477B2 (en) | 2005-04-22 | 2008-05-06 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
| CA2605580A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzodioxane and benzodioxolane derivatives and uses thereof |
| WO2007146890A2 (en) * | 2006-06-09 | 2007-12-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| CN107406369B (zh) | 2014-12-09 | 2021-01-15 | 以西结·戈兰 | 放纵行为调节剂 |
| US11045454B2 (en) | 2018-12-06 | 2021-06-29 | Palo Alto Investors LP | Methods of treating food allergy conditions |
| JP2023515616A (ja) | 2020-02-28 | 2023-04-13 | ユニヴェルシテートスピタル バーゼル | ５ｈｔ２ａアゴニストの投与後の抑制効果 |
| WO2021225796A1 (en) | 2020-05-05 | 2021-11-11 | Universitätsspital Basel | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics |
| CN116075300B (zh) | 2020-06-08 | 2025-08-05 | 泰科根公司 | 用于精神障碍或精神增强的有利苯并呋喃组合物 |
| BR112022025317A2 (pt) | 2020-06-15 | 2023-01-03 | Univ Basel | Método de dosagem de um empatógeno/entactógeno no tratamento de pacientes; método para determinar uma dose de um empatógeno/entactógeno com base no peso corporal, sexo e atividade de cyp2d6; método para refinar a dosagem de um empatógeno/entactógeno; método para predizer a dosagem futura com um empatógeno/entactógeno; método para avaliar a viabilidade de pacientes para receber um empatógeno/entactógeno como tratamento; e método para otimizar o tratamento com empatógeno/entactógeno em um paciente |
| TW202216676A (zh) | 2020-07-06 | 2022-05-01 | 美商塔朵根公司 | 用於心理疾病或心理強化的有益苯并噻吩組合物 |
| EP4192451A4 (en) | 2020-08-05 | 2024-08-14 | Universitätsspital Basel | METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY |
| CN116209657A (zh) | 2020-08-06 | 2023-06-02 | 泰科根公司 | 用于精神障碍或增强的2-氨基茚满化合物 |
| AU2021343525A1 (en) | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
| CA3199184A1 (en) | 2020-11-18 | 2022-05-27 | Felix Lustenberger | Mdma prodrugs to assist psychotherapy |
| WO2022109050A1 (en) | 2020-11-18 | 2022-05-27 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds |
| CA3203642A1 (en) | 2020-12-02 | 2022-06-09 | The Johns Hopkins University | Restoration of motor function post-neurological injury using psychedelics |
| AU2022382937A1 (en) | 2021-11-03 | 2024-05-16 | Tactogen Inc | Indolizine compounds for the treatment of mental disorders or mental enhancement |
| WO2023107653A2 (en) | 2021-12-08 | 2023-06-15 | Tactogen Inc | Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement |
| CA3239514A1 (en) | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
| NL2031332B1 (en) | 2022-03-18 | 2023-09-29 | Plethora Therapeutics B V | Transmucosal delivery of psychoactive compounds |
| WO2023183613A2 (en) | 2022-03-24 | 2023-09-28 | Tactogen Inc | Indolizine compounds for the treatment of mental disorders or inflammation |
-
2021
- 2021-06-08 CN CN202180059254.9A patent/CN116075300B/zh active Active
- 2021-06-08 JP JP2022576058A patent/JP2023530092A/ja active Pending
- 2021-06-08 WO PCT/US2021/036479 patent/WO2021252538A2/en not_active Ceased
- 2021-06-08 CN CN202411330120.8A patent/CN120040398A/zh active Pending
- 2021-06-08 AU AU2021289434A patent/AU2021289434A1/en active Pending
- 2021-06-08 CA CA3179785A patent/CA3179785A1/en active Pending
- 2021-06-08 KR KR1020237000741A patent/KR20230066313A/ko active Pending
- 2021-06-08 EP EP21822381.6A patent/EP4161503A4/en active Pending
- 2021-06-08 MX MX2022015613A patent/MX2022015613A/es unknown
- 2021-06-08 IL IL298769A patent/IL298769A/en unknown
-
2022
- 2022-12-08 US US18/077,966 patent/US11767305B2/en active Active
-
2023
- 2023-09-22 US US18/371,935 patent/US12365661B2/en active Active
-
2024
- 2024-09-24 US US18/895,095 patent/US12344591B2/en active Active
-
2025
- 2025-02-13 US US19/053,277 patent/US12404257B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023530092A5 (https=) | ||
| ES2261234T5 (es) | Metabolitos de bupropion y metodos de sintesis y uso. | |
| JP2022109989A (ja) | 異常不随意運動障害の処置のための方法 | |
| JP2025024102A (ja) | 神経障害および神経障害の処置方法 | |
| US11738002B2 (en) | Methods of treating neurological and psychiatric disorders | |
| JPS62230722A (ja) | 肥満および／または関連状態の治療剤 | |
| CN110418644A (zh) | 包含jak抑制剂的药物组合物 | |
| CN115190815A (zh) | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 | |
| JP2020063305A (ja) | 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質 | |
| TW201247613A (en) | Ester derivatives of bimatoprost compositions and methods | |
| DE69607904T2 (de) | Potenzierung von Serotonin-Wirkstoffresponz | |
| JP2023544716A5 (https=) | ||
| TW201231055A (en) | Novel medicament combinations for the treatment of respiratory diseases | |
| JP2025508071A (ja) | 純粋な形態の結晶質アチカプラント | |
| JP2023548429A (ja) | パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） | |
| JP6605447B2 (ja) | ジスキネジアおよび関連障害を治療する方法 | |
| JPH06509318A (ja) | トロポロン誘導体ならびに虚血性疾患を予防および治療するためのその薬剤組成物 | |
| CA2915811C (en) | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders | |
| TWI267510B (en) | Pharmaceutical salts of reboxetine | |
| CN106279071B (zh) | 苯基哌嗪衍生物及其使用方法和用途 | |
| JP6031217B1 (ja) | 水性液剤 | |
| JP2009519266A (ja) | 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア類 | |
| CN115960080B (zh) | 一种多环化合物及其作为胃饥饿素受体激动剂的用途 | |
| JP2009514920A (ja) | 糖尿病性神経障害を処置するためのジアリールウレア | |
| JP2025500344A (ja) | 睡眠時無呼吸の治療のためのα２－アドレナリン受容体サブタイプＣ（アルファ－２Ｃ）アンタゴニストとノルエピネフリン再取込み阻害薬との組合せ |